Pharming Group N.V., a biopharmaceutical company ... It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.

The company has initiated phase 2 studies for genetic PID and CID, which could significantly expand the addressable patient population. Pharming Group (PHGUF) has successfully reduced its ...

I would like to thank Jeroen Wakkerman for his contributions to the growth of Pharming and the development ... identified independently of genetics. Leniolisib, by modulating PI3Kδ activity ...

Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 ...

Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming ...

Leiden, the Netherlands, May 8, 2025: Pharming Group N.V. (“Pharming ... with immune dysregulation identified independently of genetics. Leniolisib, by modulating PI3Kδ activity, could ...

Pharming Group (PHGUF) reports a 42% revenue increase, driven by Ruconest and Joenja sales, while navigating acquisition costs and potential tariff challenges.

RUCONEST® demonstrated significant strength in the first quarter of 2025, with revenues of US$68.6 million, a 49% increase compared to the first quarter of 2024. The U.S. market contributed 97% of ...